Amneal Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Amneal Pharmaceuticals (AMRX) Misses Q2 EPS by 1c; Offers FY22 Guidance
August 5, 2022 6:02 AM EDTAmneal Pharmaceuticals (: AMRX) reported Q2 EPS of $0.19, $0.01 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $559 million versus the consensus estimate of $534.44 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2022 EPS of $0.65-$0.70, versus the consensus of $0.81. Amneal... More
